The effects of dietary intervention on HIV dyslipidaemia: a systematic review and meta-analysis. by Stradling, Clare et al.
The Effects of Dietary Intervention on HIV Dyslipidaemia:
A Systematic Review and Meta-Analysis
Clare Stradling1,2*, Yen-Fu Chen2, Tracy Russell3, Martin Connock4, G. Neil Thomas5, Shahrad Taheri1,2,6*
1HIV Metabolic Clinic, Heart of England NHS Foundation Trust, Birmingham, United Kingdom, 2 Birmingham and Black Country NIHR CLAHRC, University of Birmingham,
Birmingham, United Kingdom, 3Dietetic Department, Western General Hospital, Edinburgh, United Kingdom, 4Warwick Evidence, Warwick Medical School, University of
Warwick, Coventry, United Kingdom, 5 School of Public Health, Epidemiology and Biostatistics, University of Birmingham, Birmingham, United Kingdom, 6 School of
Clinical and Experimental Medicine, University of Birmingham, Birmingham, United Kingdom
Abstract
Background: Efficacy of dietary intervention for treatment and prevention of HIV-related lipid disturbances has not been
well established.
Methods: We conducted a systematic search of electronic databases supplemented with manual searches and conference
abstracts, without language restriction. All randomised controlled trials (RCTs) with blood lipid outcomes, involving dietary
intervention or supplementation for the treatment or prevention of adult HIV dyslipidaemia, versus no or other intervention
were included. Two authors using predefined data fields, including study quality indicators, extracted data independently.
Results: Eighteen studies (n = 873) met our inclusion criteria. Seven RCTs for omega-3 supplementation (n = 372), and four
RCTs for dietary intervention (n = 201) were meta-analysed using random-effects models. Mild statistical heterogeneity was
observed. Dietary intervention reduced triglyceride levels by 20?46 mmol/l (95%CI: 20?85 to 20?07 mmol/l) compared to
control. Omega-3 supplementation reduced triglyceride levels by 21.12 mmol/l, (95%CI: 21?57 to 20?67 mmol/l) and total
cholesterol, 20?36 mmol/l (95%CI: 20?67 to 20?05 mmol/l) compared to placebo/control.
Conclusions: Both omega-3 supplementation and dietary intervention reduced triglyceride level, with the latter possibly to
a smaller extent. While dietary interventions are beneficial, more stringent dietary approaches may be necessary to fully
address lipid disturbances in HIV patients.
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Introduction
While survival with HIV has increased dramatically with highly
active antiretroviral therapy (ART), affected individuals are
experiencing metabolic complications including insulin resistance
and dyslipidaemia, that ultimately translate to increased cardio-
vascular disease (CVD). Current guidelines recommend dietary
intervention as first line treatment for HIV dyslipidaemia, [1,2,3]
based on evidence from the general population, where it has been
shown to reduce CVD risk and mortality. [4,5] Whether these
findings can be extrapolated to the HIV population on ART is
unknown. If dietary interventions were effective, CVD risk can be
reduced through behaviour modification reducing toxicity and pill
burden accompanying lipid-lowering medication (LLM).
Narrative reviews have examined the broader management of
HIV dyslipidaemia including drug intervention, [6] and the effect
of nutritional support and exercise on body composition. [7]
Almeida et al examined dietary intervention from observation and
intervention studies, concluding that there was little evidence for
effectiveness of dietary interventions for HIV dyslipidaemia. [8]
We hypothesized that dietary interventions have a beneficial effect
on HIV dyslipidaemia and carried out a systematic review and
meta-analysis of randomised controlled trials (RCTs) assessing the
efficacy of dietary interventions or supplementation for HIV
dyslipidaemia.
Methods
Current guidelines for systematic reviews were followed [9]
including protocol registration (PROSPERO
2011:CRD42011001329).
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Search Strategy
A comprehensive search was conducted using a combination of
MeSH and free text terms incorporating the population (HIV
infected adults), intervention (any dietary therapy or supplements)
and outcome (cardiovascular or dyslipidaemia), limited to human
studies and clinical trials, up to 15 March 2012 on databases from
Medline (OVID from 1950), AMED (from 1985), CINAHL (from
1981), EMBASE (from 1988), and up to 31 May 2011 on
OpenSIGLE (from 1980) and Cochrane Library, and clinical trial
registries including the World Health Organisation and National
Institutes of Health (Table S1). No language restrictions were used.
The International AIDS Conference (2001 to 2010) and Confer-
ence on Retroviruses and Opportunistic Infections (1997 to 2010)
websites were searched by use of the term ‘diet’.
Selection Criteria
Articles resulting from these searches and relevant references
cited in those articles were screened and assessed independently by
two reviewers (CS and TR) for eligibility. All RCTs involving
dietary intervention or nutritional supplementation given for
prevention or treatment of HIV metabolic disturbances in adults
were included.
All-cause mortality or cardiac events were preferred as primary
outcomes, however frequent reporting of these was not anticipated
therefore surrogate markers such as change in serum lipids, were
also sought. The control group was usual diet, no intervention or
placebo; however, head to head intervention studies were also
included. Studies lacking a control, or dietary intervention, or
those whose primary focus was not prevention or treatment of
metabolic disturbances were excluded. Duplicate publications
were also excluded.
Validity Assessment
Study level risk of bias was assessed (independently in duplicate)
using the Cochrane Collaboration 6-item domain based evalua-
tion (version 5?0). [10] Diet specific factors, such as intervention
adherence and potential confounding lifestyle factors (smoking,
exercise, alcohol) were incorporated into the performance bias
section (see Figure S1). A score of 21, 0, +1, was assigned to
judgments ‘high’, ‘unclear’, and ‘low’ risk, respectively, for the
purpose of study quality categorisation used to inform sensitivity
analysis. Score consensus was reached following discussion of each
study.
Data Extraction
Piloted forms and duplicate standardised databases were used
by two reviewers to independently extract the following data: study
characteristics (design, setting, enrolment date, sample size,
eligibility criteria, quality, funding, ethics), population studied
(baseline characteristics – lipids, body mass index, smoking, ART,
ethnicity, age, gender, LLM), therapeutic interventions (duration,
intensity, advice specifics regarding diet, exercise, smoking and
adherence to it, comparison of intakes), and control regimen.
Outcomes assessed included serum total cholesterol (total choles-
terol), high-density lipoprotein cholesterol (HDL-cholesterol),
Low-density lipoprotein cholesterol (LDL-cholesterol), and triglyc-
eride (TG) levels. Discrepancies were resolved by discussion and
comparison with the primary study report.
Data Analysis
No studies reported clinical endpoints, therefore outcome data
(baseline and final mean values with standard deviation, SD) for
total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyc-
eride was extracted and converted to SI units. Authors were
contacted for missing outcome data or raw data where non-
parametric outcomes were presented and to clarify discrepancies.
In absence of author response, the SD of the outcome mean for
intervention and control groups was estimated from the respective
standard error or confidence intervals if reported, or the p value of
the mean difference between groups. In absence of reporting of
final means, or where there was a significant difference between
intervention and control group baseline values, change from
baseline was used in the meta-analysis. Where clinical homoge-
neity allowed, effect sizes were pooled, and weighted by inverse
variance of each study’s effect estimate. Studies reporting
insufficient data were excluded from meta-analysis.
The principal summary measure was difference in mean lipid
levels (total cholesterol, LDL-cholesterol, HDL-cholesterol, tri-
glyceride) post-intervention between groups. Due to broad
eligibility criteria regarding dietary intervention, clinical hetero-
geneity was expected and a random effects model planned.
Statistical heterogeneity was quantified using I2 statistic and
assessed for strength of evidence using the chi-squared test.
Subgroup analysis was planned a priori where heterogeneity was
anticipated between studies, arising from variations in baseline
characteristics (normal or elevated lipid levels, use of LLM, use of
ART), treatment type and duration, and comparators. Dose
related response for omega-3 supplements was explored using
meta-regression. Sensitivity analyses were pre-planned to assess
the effect on the pooled result of exclusion of studies with small
sample size (defined as less than 30 participants), studies of low
quality, based on the risk of bias score (,2), unpublished studies,
and inclusion of change scores within the analysis based on final
values. Publication bias was explored using funnel plots where
numbers of studies allowed (.10). Data were analyzed using
RevMan 5?0 (The Cochrane Collaboration, UK) [11] and
STATA 10 (StataCorp LP, Texas, USA).
Results
Literature searches retrieved 606 citations; after screening and
exclusion, 43 articles were further scrutinised. (Excluded studies
are listed in Figure S2). Eighteen primary studies met selection
criteria (Figure 1). Three of these were from conference
proceedings, available only in abstract form [12], [13] or with
additional information from authors [14].
Study Characteristics
Table 1 shows key characteristics of included studies. Of 18
RCTs, seven were placebo-controlled, [12,15,16,17,18,19,20] and
two used an alternative comparator, fenofibrate [21] or Mediter-
ranean diet (MD). [22] All studies were in English, mainly from
North America (n = 10), with some from Europe, [15,17,20] east
Asia, [13,16,22] and South America. [14,23] Median study
duration was 12 weeks (range: 8–16 weeks) for tablet (omega-3/
other supplementation) studies and 26 weeks (range: 16–52 weeks)
for diet studies. Sample sizes ranged from 11–120 participants
(median: 46).
The majority of studies (12/18) involved specific nutrient
supplementation: nine with omega-3 (daily dose range: 900–
4860 mg total eicosapentaenoic acid [EPA] and docosahexaenoic
acid [DHA]; Table S2), three of which also included vitamin E.
[20,21,24] Others employed a form of nicotinic acid [18,25] or
chromium. [19].
Six studies evaluated dietary interventions. Due to lack of full
text publication, very little was reported on dietary components of
the symptom management model in one of the studies, [13] but
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other studies were based on advice following the NCEP ATPIII
dietary recommendations [26]. The specifics of these five diet
studies varied, such as level of fibre, and inclusion of exercise,
[14,23,27,28] whilst two studies also provided meals for 2–3 weeks
[24,28] (Table S3). Intervention intensity varied from daily online
support [28] or weekly individual counselling for six months, [27]
to fortnightly [14] and three-monthly sessions. [23] Control groups
in diet studies received usual care.
Most of the 873 participants in included studies were men
(Table 2). Ethnicity ranged from 100% Chinese [22] and 100%
Thai, [13] to most studies containing both African and Caucasian
participants. Mean age ranged from 38–50 years. Mean baseline
fasting triglyceride levels ranged 1?51–7?54 mmol/l and total
cholesterol 3?94–6?24 mmol/l. Participants were generally on
stable ART with hypertriglyceridaemia, except the Brazilian study
where patients naı¨ve to ART with and without dietary advice were
observed for dyslipidaemia development. [23] The Chinese study
mainly recruited newly diagnosed HIV patients. [22] Use of ART
regimens containing protease inhibitors (PI) ranged from 14–82%.
Studies mainly assessed fasting blood lipids as primary outcome; in
two studies, blood lipids were secondary outcomes after waist
circumference [27] and insulin resistance. [19].
Risk of Bias
Most studies were classified as low to moderate risk for selection,
attrition, reporting and performance bias (Figure 2). Lack of
blinding was the most common reason for high bias risk (Figure
S3) and in diet studies this might have resulted in the control group
also changing their diet due to trial participation, potentially
producing bias against observing an effect of the intervention.
Other main reasons for high bias risk were lack of information
about attrition, lack of intention to treat analysis or power
calculation, and potential imbalance at baseline in use of alcohol,
cigarettes, or exercise. Randomisation information lacked clarity
in half of studies.
Diet Studies
Among the six diet studies, two studies were excluded from
meta-analysis due to lack of data, [13] and head-to-head design.
[22] The pooled estimate for four studies (n = 201) [14,23,27,28]
showed no significant differences between dietary intervention and
control groups for total cholesterol (0?01 mmol/l; 95%CI 20?71
to 0?73, p = 0?97, I2 = 85%), HDL-cholesterol (0?11 mmol/l;
95%CI 20?01 to 0?22, p = 0?07, I2 = 33%), and LDL-cholesterol
(3 studies; 20?01 mmol/l, 95%CI 20?81 to 0?79 mmol/l,
p = 0?98, I2 = 87%); and there was evidence of substantial
statistical heterogeneity. Reduction in fasting triglycerides was
significantly greater with dietary intervention versus controls, the
random effects point estimate was: WMD 20?46 mmol/l, 95%CI
20?85 to 20?07 mmol/l (p = 0.02) (Figure 3) with moderate
statistical heterogeneity (I2 = 30%).
Similar treatment effect estimates were found on sensitivity
analysis with exclusion of small trials (,30 participants), [27]
duration of less than six months, intervention including exercise,
Figure 1. Prisma flow diagram of study selection and exclusion.
doi:10.1371/journal.pone.0038121.g001
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[14,27,28] change scores rather than final value, [14] unpub-
lished trials [14,23] and those with high bias risk [23] (data not
shown).
Omega-3
Of the nine omega-3 studies, two were excluded from meta-
analyses due to lack of data [12] and head-to-head design [21]
(Table S4). The excluded omega-3 trials illustrated extremes in
both omega-3 doses and outcomes, from 13% reduction in
triglyceride with 300 mg omega-3, [12] to 46% triglyceride
reduction with 4860 mg omega-3 (versus 58% in fenofibrate
comparison group). [21] Seven studies (n = 372) reported results
for fasting triglycerides and total cholesterol and were included in
meta-analysis. There was a significantly greater reduction in
fasting triglycerides among those receiving omega-3, compared to
controls; random effects point estimate 21.12 mmol/l, 95%CI
21.57 to 20.67 mmol/l (p,0?0001, I2 = 5%) (Figure 3). Total
cholesterol reduction (20?36 mmol/l, 95%CI 20?67 to
20?05 mmol/l, I2 = 35%) (Figure 4) was significant (p = 0.02)
when SD imputation used the average from other studies
(SD = 1.23 and 1.24) as planned a priori, but was of borderline
statistical significance (p = 0?05) when alternative SD imputation
(at ‘reasonably high’ value SD = 1.5) was used in sensitivity
analysis.
The pooled estimate from five studies (n = 240) indicated no
significant difference between intervention and control groups for
LDL-cholesterol (0?10 mmol/l, 95%CI 20?15 to 0?35 mmol/l,
p = 0?43, I2 = 0%), and the pooled estimate for 6 studies (n = 365)
similarly indicated no difference for HDL-cholesterol (0?05 mmol/
l, 95%CI 0?00 to 0?11 mmol/l, p = 0?07, I2 = 0%, Figure S5).
Sensitivity analyses showed that methodological heterogeneity
did not appear to influence effect estimates; the six studies with
sample sizes .30 [15,17,20,24,29,30] and the four trials meeting
quality criteria [15,17,20,29] produced results similar to the
overall meta-analysis (triglycerides MD 21.10 mmol/l, 95%CI
21?60 to 20?61 and 21.10 mmol/l, 95%CI 21?82 to 20?39,
respectively).
Subgroup analysis, according to whether placebo was used in
the trial, did not demonstrate any differences in treatment effects
(test for subgroup difference, triglyceride p = 0?62, total cholesterol
p = 0?89). A significant difference in treatment effect between
LLM subgroups, for cholesterol only, was found (test for subgroup
difference p = 0?01), with trials allowing LLM use showing no
significant treatment effect (20?14 mmol/l, 95%CI 20?44 to
0?17) compared with those excluding LLM use (20?81 mmol/l,
95%CI 21?25 to 20?37) (Figure 4). Thus, the moderate statistical
heterogeneity among omega-3 studies for reduction in total
cholesterol (I2 = 35% as shown earlier) is likely due to the
variability in exclusion criteria in relation to LLM use.
Risk stratification of studies suggested possible trends of
increasing treatment effect with greater underlying risk, as defined
by baseline triglyceride levels (Figure 3). Further exploration with
meta-regression, however, found no evidence of a significant
association between either baseline triglyceride levels (p = 0?1 and
p = 0?6), omega-3 dose (p = 0?9 and p = 0?7) or proportion of
participants on PI-based regimens (p = 0?4 and p = 0?6) and mean
difference in triglycerides or total cholesterol, respectively, between
intervention and control groups. Although the meta-regression
was planned a priori, the small number of trials limited the
statistical power of analyses, which remain exploratory.
Publication Bias
Small statistical heterogeneity was observed in the diet and
omega-3 meta-analyses for triglycerides (I2 = 30%, p = 0?23 and
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I2 = 5%, p = 0?39, respectively). There was some evidence of
asymmetry in the funnel plot (Figure S6). Potential causes include
publication bias, genuine small study effects, and statistical
heterogeneity; the latter was small and an unlikely explanation.
[31] Formal testing of statistical significance of the asymmetry was
not undertaken because of the small number of studies.
Other Supplementation
Three studies were excluded from the meta analyses above due
to their use of other forms of supplementation, rather than omega-
3 or dietary intervention. Two small studies investigated the use of
nicotinic acid analogues, reporting a significant reduction in
triglyceride 20.54 mmol/l versus placebo +0.65 mmol/l
(p = 0.01) in one, [18] and a significant increase in HDL-
cholesterol +0.08 mmol/l compared to control group
20.03 mmol/l (p = 0.04) in the other. [25] Chromium supple-
mentation was associated with improvement in insulin resistance
and a significant reduction in triglycerides 20.54 mmol/l
(p = 0.03) in one study, where the effect was greater in participants
with lipodystrophy 20.7860.30 mmol/l compared to those
without 0.1460.19 mmol/l (p = 0.017) [19] (Table S4).
Head-to-head Studies
A head-to-head study found no clinically significant difference
in treatment effect between MD versus low fat diets (LFD). [22]
The interventions appeared to differ in delivery rather than
content. Trends for reducing total cholesterol levels with LFD, but
maintaining triglyceride levels with MD were seen. Lack of study
exclusion criteria resulted in a varied sample including unstable
patients, those newly diagnosed with HIV or recently commenced
on ART (Tables 2 and S4). [22].
Discussion
Findings
Dietary change is recommended to address deleterious lipid
profiles predisposing to CVD in HIV patients. We did not find any
studies reporting cardiovascular outcomes with dietary interven-
tion in this patient population, therefore the objective outcome
measures of serum lipids were used. Our meta-analysis revealed
that a median dose of 2.8 g/d omega-3 was effective in reducing
fasting triglycerides by 21.12 mmol/l over an average treatment
period of 12 weeks. Likewise NCEP Therapeutic Lifestyle
Changes diets (TLC) [26] reduced fasting triglyceride reduction
by 20?46 mmol/l over an average treatment period of eight
months in ART treated patients. Importantly, no significant effect
on HDL-cholesterol or LDL-cholesterol was seen with either diet
or omega-3 intervention, and only a minor reduction in total
cholesterol was observed with omega-3 supplementation. These
findings have good external validity coming from 5 different
continents.
Interpretation of Findings
Dietary Intervention. In the general population, current
evidence from meta-analyses suggest that dietary intervention
reduces triglycerides by 20?12 mmol/l (18?2%) with TLC style
diets and exercise. [32] Previous reports of reductions of
20?17 mmol (8%) and 20?19 mmol/l (8%) with the Step I and
Step II NCEP diets, respectively, may have been over estimated by
outdated statistical approaches. [33] These are somewhat less than
the reduction observed in our pooled estimate, presumably
because of differences in baseline triglyceride levels (mean
2.20 mmol/l in the 3 HIV population diet studies versus
0.98 mmol/l in the general population studies [32]).
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The lack of a beneficial effect of diet on HDL-cholesterol levels
in our analysis, also observed by other reviews, [32,33] was
potentially due to the diets’ emphasis on lowering saturated fat
which also reduces HDL-cholesterol. [33,34] The positive effects
of exercise on HDL-cholesterol [35,36] may also be insufficient to
override the lowering effect of diet. [32].
We observed no differences for LDL-cholesterol. This was
unexpected, as previous meta-analyses in the general population
have shown significant reductions in LDL-cholesterol with diet.
Reasons for this are uncertain but may include lack of diet
intensity and adherence. Evidence from meta-analyses suggest
an incremental effect on lipid lowering with diet intensity, from
an LDL-cholesterol reduction of 20?18 mmol/L (95%CI 0?1 to
0?27) with general dietary advice [37] to 20?49 mmol/l (12%)
with Step I, and 20?65 mmol/l (16%) with Step II NCEP diets.
[33] Recent RCTs suggest that this treatment effect may be
magnified with addition of a ‘portfolio’ of cholesterol-lowering
foods: plant sterols, soy protein, viscous fibre, and almonds, to
produce an LDL-cholesterol reduction 21?36 mmol/l (28?6%)
in feeding trials. [38] However, when performed under real-life
conditions, the LDL-cholesterol reduction was 20?67 mmol/l
(13?8%) due dietary adherence of only 46%. [39] Higher
intensity dietary interventions may also be required in the HIV
population for LDL-cholesterol reduction. Changes in LDL-
cholesterol may have been limited in the included studies by
adherence, as measures revealed that although significant
improvements to dietary intake were made with regard to fat
and fibre, levels attained did not reach the goals set
[23,24,27](Figure S4). The significant reduction in total choles-
terol observed in one of the included studies at week 3
(following controlled feeding), but not at week 13 [24] further
supports the importance of dietary adherence, suggesting that
dietary interventions may be difficult to implement in real-life,
also seen in uncontrolled studies. [40].
Another difficulty with dietary interventions is establishing
which components alter the outcome of interest and whether they
act independently, synergistically or accumulatively. The magni-
tude of effect observed in the Woods study [24] could be explained
by the dietary intervention enhancing triglyceride reduction as
well as improving HDL-cholesterol levels synergistically with
omega-3. It is unlikely that the addition of exercise [14,27] would
affect the outcome of dietary intervention alone, as this intensity
and duration of exercise has previously proved insufficient to
reduce triglycerides. [41,42,43,44].
Omega-3. Our study supports a role for omega-3 supple-
mentation in primary treatment of hypertriglyceridaemia in HIV
patients. A systematic review in patients with diabetes (mean dose
3?5 g/d fish oil) reported similar reductions in triglycerides. [45] In
primary prevention, from 47 RCTs (16,511 subjects), a mean dose
3?25 g/d and duration 24 weeks, reduced triglyceride by
20?34 mmol/l (95%CI 20?41 to 20?27) from mean baseline
2?44 mmol/l. [46] The magnitude of triglyceride reduction was
significantly related to baseline triglyceride and fish-oil dose, but
not duration. We observed no evidence of a dose effect, probably
due to the small number of studies; however in the general
population, a 5–10% reduction in triglycerides has been reported
with every 1 g of EPA/DHA consumed. [47] Subgroup analysis in
our review revealed significant total cholesterol reduction with
omega-3 in patients who were not on statin therapy, highlighting
the importance of explicit exclusion criteria in trials, as concurrent
LLM likely masked the effect.
Omega-3 supplementation has a triglyceride-lowering effect
that may impact on cardiac outcomes. Previously meta-analyses
reported reductions in mortality and cardiovascular events
[48,49,50] in patients with existing CVD who were taking fish
oil supplements. However, they may have been subject to
publication bias as inclusion of more recent trials (GISSI-
HF,OMEGA, JELIS) produce pooled analyses of non-significant
reduced mortality risk. [51] This suggests that doses of 1 g/d
omega-3 cannot reduce mortality risk further than provided by
optimised drug treatment. JELIS results suggest that the dose-
dependent effect of EPA may be linked to reduction in
Figure 2. Risk of bias summary. Review authors’ judgements about
each risk of bias item for each included study.
doi:10.1371/journal.pone.0038121.g002
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triglycerides that is distinct from LDL-cholesterol reduction with
LLM. Similarly, evidence from previous reviews that fish oil
supplementation was associated with significant reduction in
cardiac deaths [50] suggests that the higher dose 3–4 g/d
needed to reduce triglycerides, inflammation, increase vascular
reactivity, and reduce platelet function [52] may be more
appropriate for primary and secondary prevention; therefore
trials are required with higher doses.
Strengths and Limitations
Previous reviews have been narrative and examined the broader
management of HIV dyslipidaemia. McGoldrick et al focused on
drug intervention as their search criteria and did not identify any
Figure 3. Forest plot for effect of various dietary interventions on triglyceride levels (mmol/l). Studies are ranked from low to high
baseline triglyceride levels. Illustrates weighted mean difference in triglyceride levels between dietary intervention or omega-3 supplementation and
control group.
doi:10.1371/journal.pone.0038121.g003
Figure 4. Forest plot for effect of omega-3 supplementation on cholesterol levels (mmol/l). Studies are ranked from low to high baseline
cholesterol levels. Illustrates subgroup analysis of concurrent use of lipid lowering medication (LLM) on treatment effects of omega-3
supplementation on Cholesterol levels.
doi:10.1371/journal.pone.0038121.g004
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trials concerning diet or supplements. [6] Leyes et al described 4
intervention trials, 2 open label and 2 randomised, studying only
the effect of statin therapy and exercise levels, but not diet. [7] The
most recent narrative review concluded that there was little
evidence on effectiveness of dietary interventions for prevention
and control of HIV dyslipidaemia. [8] Our systematic review is the
first to employ a comprehensive search strategy and meta-analysis
and demonstrates a role for dietary intervention.
While results of this review are encouraging, they must be
viewed with caution due to several limitations. The small number
of dietary intervention studies included in the analyses, their small
sample sizes and inclusion of participants with mild dyslipidaemia
limited the capacity to detect changes in lipids due to Type 2 error.
Whilst statements can be made regarding the effectiveness of
omega-3 supplementation and hypotheses can be proposed
regarding dietary intervention, the limited number of studies
available for each specific intervention do not allow us to make
definitive statements about the individual effectiveness of NCEP
diets, niacin or chromium.
Also, regarding validity, most studies either had some
methodological weakness or had certain elements of methodol-
ogy inadequately reported (Figure 2, Figure S3). All diet studies
lacked blinding, which is problematic in diet studies. Addition-
ally, it is difficult to have an appropriate control intervention.
[53].
Despite lack of evidence of statistical heterogeneity in the meta-
analyses for triglycerides, clinical heterogeneity was anticipated
between dietary intervention studies due to variations in interpre-
tation of the extensive NCEP ATPIII diet guidelines (Table S3).
Additionally, study objectives differed, where one [23] examined
dietary intervention to prevent dyslipidaemia, whilst others sought
to correct dyslipidaemia/lipodystrophy. [14,23,27] Omega-3
studies included for meta-analysis were clinically homogeneous
vis-a`-vis intervention, control, duration and outcome; the main
variations included differing participant ethnicities, facilitating
transferability of findings, and baseline triglyceride levels or
omega-3 dose, which were examined through ranking (Figure 3).
The underlying causes of dyslipidaemia and whether they were
due to direct HIV drug effects could not be quantified due to the
variety of ART used, however, treatment regimens remained
unchanged for the duration of the studies.
Another issue was the general incomplete reporting of study
design and outcome data, as this hampered synthesis of included
studies, requiring estimation of standard deviations in four studies.
Risk of bias was difficult to assess with respect to allocation
concealment, and selective outcome reporting (Figure 2). Future
studies need to also include data on potential confounding factors
such as other lifestyle factors (e.g. use of alcohol, tobacco, physical
activity), or treatment modalities (e.g. protease inhibitors).
Clinical Implications
Current HIV guidelines recommend diet and exercise as first line
treatment. Given the limitations of available studies, our findings
support a role for diet with respect to triglycerides, but not other
lipids. Omega-3 supplementation was effective in lowering triglyc-
erides and total cholesterol, but had no impact on LDL-cholesterol
or HDL-cholesterol. Omega-3 supplementation is recommended as
second line therapy to fibrates in American guidelines. [1] The 25%
triglyceride reduction from omega-3 in our pooled analysis is nearly
comparable to the 30% triglyceride reduction reported with fibrates
in the general population. [54] Therefore, in ART-treated HIV
patients, omega-3 may to be an alternative to fibrates, which may
not be well tolerated and interact with PIs. Also, the total cholesterol
reduction with omega-3 may obviate the need for statins, and their
attendant side effects, in patients with primarily high triglycerides.
Recent reviews have both questioned the role of omega-3 in
cardiovascular event or mortality reduction [55] and reported a
reduction in cardiac and overall mortality with omega-3 supple-
mentation. [56] Specific studies are needed to examine these
outcomes in ART treated HIV patients. Triglyceride levels
represent an important biomarker of CVD, because of their
association with atherogenic remnant particles [57] and their
independent association with an increased risk of MI, seen in the
prospective HIV DAD cohort. [58] However, the effect of diet on a
single biomarker cannot be independently considered, and overall
CVD risk should be considered.
Conclusions
Available studies have only reported on impact of dietary
intervention on surrogate lipid markers in ART-treated HIV
patients. Regarding lipid markers, our meta-analysis provides
evidence for a comparable clinical benefit of dietary intervention
or omega-3 supplementation in reducing triglycerides, but no
effects on other lipids in patients without concurrent LLM.
Our findings support the view that lifestyle interventions are a
reasonable first strategy in clinical practice to improve lipid profile.
Current dietary approaches, however, may be insufficient to
independently tackle HIV dyslipidaemia and associated CV risk.
Studies with interventions of sufficient duration and intensity,
including a wide range of cholesterol lowering dietary compo-
nents, focusing on foods rather than nutrients are required to
elucidate the full potential of dietary intervention on lipid
biomarkers and CVD. These studies would benefit from both
efficacy (as treated) and effectiveness (intention to treat) analyses to
address proof of principle for individual dietary components and
whether they reduce CVD in clinical practice.
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